Juvaris touts vaccine adjuvant response; new research on diabetes vax

Vaccine Research

Juvaris BioTherapeutics says that clinical results demonstrate that its vaccine adjuvant, JVRS-100, when combined with a trivalent inactivated seasonal flu vaccine, generated robust T-cell mediated immune responses and antibody responses. Release

PhD student Eliana Mariño and Dr Shane Grey, from the Garvan Institute of Medical Research in Sydney, have demonstrated how a particular molecule may be used in future as a preventative therapy for Type 1 diabetes. Their findings are published online in the international journal Diabetes. Release

VaxInnate is touting Phase I data for its seasonal flu vaccine VAX 125. "VaxInnate's HA vaccine candidate for seasonal flu has passed a critical initial test," said David Taylor, MD, Chief Medical Officer. "We're encouraged by these data, which show that VAX125 is safe and elicits a potent immune response at sub-microgram doses. That's particularly impressive when you consider that the dose of conventional flu vaccines in use today is 15 micrograms for each component." Release

Dynavax Technologies announced the oral presentation of additional Phase III clinical data for HEPLISAV hepatitis B vaccine in a session for late-breaking abstracts at the 44th Annual Meeting of the European Association for the Study of Liver Disease in Copenhagen, Denmark. Release

Vaccine market

Wyeth reported that sales of its vaccine Prevnar, a jab that is designed to guard children from pneumococcal bacteria, jumped seven percent in the first quarter. Report

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.